A novel Raman-based multiplex imaging platform for breast cancer biomarkers


Competition: SynergiQc 2016
Funding: $1,037,155 / 2 years
Beginning: April 2017

Challenge: Extensive characterization of tumors is central to the development of personalized therapies such as immunotherapy, now considered one of the most promising and innovative approaches to treatments in the fight against cancer. The capability to detect a multitude of biomarkers simultaneously on the same tissue section would therefore provide unprecedented headways in the field of cancer research and particularly on tumor profiling.

Solution: In this project, the research team aims to establish a multiplex immunohistochemistry and imaging analysis platform. Building on Dr. Martel’s expertise in nanotechnology, the team will develop a method using Raman labels- single walled carbon nanotubes coupled with specific antibodies to simultaneously detect up to 15 breast cancer and immunotherapy-related biomarkers. Detection will be done using a Raman imaging system to be developed in parallel by Photon etc.

Impact: This novel multiplexed immunohistochemistry platform will offer many advantages over existing technologies including cost reduction and the reduced quantity of biological material required. This platform will allow researchers and pathologists to provide improved diagnostic classification, guidance on clinical outcome and to further develop personalized therapy for breast cancer tumors.

Richard Martel

Université de Montréal


Louis Gaboury
University of Montréal

Morag Park
McGill University